UBC Faculty Research and Publications

Mirtazapine : Update on efficacy, safety, dose response University of British Columbia. Therapeutics Initiative

Description

Therapeutics Letter 129 provides an update on the efficacy, safety and dose response for mirtazapine. Conclusions Mirtazapine’s efficacy for depression is similar to other commonly-prescribed antidepressants. It causes drowsiness, weight gain, and dry mouth. Doses above 30 mg daily provide fewer benefits but markedly increase harms. Prescribing mirtazapine for insomnia has not been validated by clinical trials. Adding mirtazapine to an SSRI or SNRI does not improve efficacy but increases harm.

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International